Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP - Takeaways - MDSpire

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP

  • By

  • Przemysław R. Kac

  • Katheryn A. Q. Cousins

  • Alicja Szadziewska

  • Leslie M. Shaw

  • Michael Turton

  • Vivianna M. Van Deerlin

  • Peter Harrison

  • Henrik Zetterberg

  • David A. Wolk

  • Corey T. McMillan

  • Douglas Galasko

  • Jörg Hanrieder

  • Edward B. Lee

  • Hlin Kvartsberg

  • David J. Irwin

  • Kaj Blennow

  • June 24, 2026

  • 0 min

Share

  • 1

    Tauopathies are neurodegenerative diseases characterized by tau protein abnormalities, with Alzheimer's disease being the most common.

  • 2

    Frontotemporal lobar degeneration due to tau (FTLD-tau) lacks robust fluid biomarkers, complicating clinical trials and diagnosis.

  • 3

    Tau368 immunoassay targets specific tau fragments, showing potential for improved diagnostic precision in FTLD-tau compared to other tauopathies.

  • 4

    The study examined tau368 immunoreactivity in postmortem brain tissue from individuals with various neurodegenerative diseases.

  • 5

    CSF biomarkers including tau368 and their ratios may enhance differentiation between Alzheimer's disease and other neurodegenerative conditions.

Original Source(s)

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP

  • by Przemysław R. Kac, Katheryn A. Q. Cousins, Alicja Szadziewska, Leslie M. Shaw, Michael Turton, Vivianna M. Van Deerlin, Peter Harrison, Henrik Zetterberg, David A. Wolk, Corey T. McMillan, Douglas Galasko, Jörg Hanrieder, Edward B. Lee, Hlin Kvartsberg, David J. Irwin, Kaj Blennow

  • June 24, 2026

Related Content

‘Are we just going to give up and die like every other generation?’

Comorbidity sequence, sex, and APOE-genotype forecast Alzheimer's disease diagnosis

Osteoimmuno-brain axis: a bridge connecting osteoporosis and cognitive decline and its clinical significance in dementia and Alzheimer’s disease